Merck to Acquire JSR Life Sciences Chromatography Business

October 19, 2025

Merck has entered into a definitive agreement to acquire the chromatography business of JSR Life Sciences. The deal is intended to expand Merck’s downstream processing portfolio—particularly Protein A chromatography capabilities used to purify monoclonal antibodies and other therapeutic proteins—and is expected to close by the end of Q2 2026, subject to customary conditions.

Buyers
Merck
Targets
JSR Life Sciences chromatography business
Sellers
JSR Life Sciences
Industry
Biotechnology
Location
Belgium
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.